Skip to main navigation
  • Medical Information
  • Facebook
  • Twitter
  • Linkedin
  • Instagram
  • Grant Portal
Catalystpharma.com
  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • Events and Presentations
    • Careers
    • Contact Us
  • Patient Focus
    • Disease Information
      • Lambert-Eaton Myasthenic Syndrome (LEMS)
      • Epilepsy
      • Duchenne Muscular Dystrophy (DMD)
    • Podcast
  • Development
    • Research
    • Pipeline (Clinical)
    • Business Development
    • Compassionate Use Programs
  • Products
    • APPROVED PRODUCTS
  • ESG Responsibility
    • Investigator Sponsored Research
    • ESG Report
      • ESG SASB DISCLOSURE
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page

Investors

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Management
    • Committee Composition
    • Board Diversity Matrix
    • Contact the Board
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla.

Events & Presentations

Mar 10, 2026 at 3:30 PM EDT
Barclays 28th Annual Global Healthcare Conference
Feb 26, 2026 at 8:30 AM EST
Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2025 Financial Results
More

Latest Press Releases

Mar 06, 2026
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Feb 25, 2026
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
More

Stock Quote

Change
Volume
52 Week High
52 Week Low
Mar 24, 2026 2:49 PM EDT
More
  • Email Alerts
  • RSS
  • Print page
  • Search
Catalyst Pharmaceuticals logo
  • ABOUT CATALYST
  • DISEASE INFORMATION
  • RESPONSIBILITY
  • EVENTS & PRESENTATIONS
  • CAREERS
  • CONTACT US
  • COMPASSIONATE USE PROGRAMS
CONTACT
(305) 420-3200
Email Us

Investors
 

FOLLOW US:

facebooktwitterlinkedininstagram
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement